Tempus AI's stock fell 5.07% in after-hours trading on Tuesday following the release of its fourth-quarter 2025 financial results.
The AI precision medicine company reported revenue of $367.2 million for the quarter, representing 83% year-over-year growth and beating analyst expectations of $362.3 million. Adjusted loss per share of $0.04 was in line with estimates.
However, investors focused on the company's Adjusted EBITDA of $12.89 million, which fell short of the $21.37 million consensus estimate. This miss appears to have driven the post-market selloff, despite the company's strong revenue growth and 2026 revenue guidance of approximately $1.59 billion with Adjusted EBITDA projected at $65 million.